Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone
- PMID: 10831489
- DOI: 10.1176/appi.ajp.157.6.1019
Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone
Abstract
Objective: The authors' goal was to study the relationship between subjective experience during treatment with olanzapine or risperidone and dopamine D(2) receptor occupancy in stabilized patients with schizophrenia.
Method: Subjective experience, psychopathology, and extrapyramidal symptoms were assessed, and D(2) receptor occupancy was determined with [(123)I]iodobenzamide single photon emission computed tomography, in 22 patients whose schizophrenia was stabilized by olanzapine or risperidone.
Results: Subjective experience, depression, and negative symptoms were related to dopamine D(2) receptor occupancy, but extrapyramidal symptoms were not.
Conclusions: These results provide preliminary evidence that negative subjective experience is related to high D(2) receptor occupancy. Longitudinal study is required because this relationship may have implications for dosing strategies.
Similar articles
-
Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.Am J Psychiatry. 2003 Feb;160(2):303-9. doi: 10.1176/appi.ajp.160.2.303. Am J Psychiatry. 2003. PMID: 12562577 Clinical Trial.
-
In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.Eur J Nucl Med. 1999 Aug;26(8):862-8. doi: 10.1007/s002590050460. Eur J Nucl Med. 1999. PMID: 10436199
-
Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia.Psychiatry Res. 1999 Nov 8;92(1):33-44. doi: 10.1016/s0925-4927(99)00032-3. Psychiatry Res. 1999. PMID: 10688158 Clinical Trial.
-
Adverse events related to olanzapine.J Clin Psychiatry. 2000;61 Suppl 8:26-9; discussion 30. J Clin Psychiatry. 2000. PMID: 10811240 Review.
-
Estimating dopamine D₂ receptor occupancy for doses of 8 antipsychotics: a meta-analysis.J Clin Psychopharmacol. 2013 Oct;33(5):675-81. doi: 10.1097/JCP.0b013e3182983ffa. J Clin Psychopharmacol. 2013. PMID: 23948784 Review.
Cited by
-
The drug-induced helplessness test: an animal assay for assessing behavioral despair in response to neuroleptic treatment.Psychopharmacology (Berl). 2007 Jan;190(1):1-11. doi: 10.1007/s00213-006-0577-y. Epub 2006 Nov 9. Psychopharmacology (Berl). 2007. PMID: 17093979
-
Behavioral and emotional adverse events of drugs frequently used in the treatment of bipolar disorders: clinical and theoretical implications.Int J Bipolar Disord. 2016 Dec;4(1):6. doi: 10.1186/s40345-016-0047-3. Epub 2016 Feb 16. Int J Bipolar Disord. 2016. PMID: 26879750 Free PMC article.
-
Effects of risperidone/paliperidone versus placebo on cognitive functioning over the first 6 months of treatment for psychotic disorder: secondary analysis of a triple-blind randomised clinical trial.Transl Psychiatry. 2023 Jun 10;13(1):199. doi: 10.1038/s41398-023-02501-7. Transl Psychiatry. 2023. PMID: 37301832 Free PMC article. Clinical Trial.
-
The dopamine augmenter L-DOPA does not affect positive mood in healthy human volunteers.PLoS One. 2012;7(1):e28370. doi: 10.1371/journal.pone.0028370. Epub 2012 Jan 4. PLoS One. 2012. PMID: 22238577 Free PMC article. Clinical Trial.
-
Impact of atypical antipsychotics on quality of life in patients with schizophrenia.CNS Drugs. 2004;18(13):877-93. doi: 10.2165/00023210-200418130-00004. CNS Drugs. 2004. PMID: 15521791 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical